Christopher Hallam (GDPO) argues for increased support toward heroin-assisted treatment (HAT) by national governments and international bodies, including the INCB.
SSDP considers that the 'drugs cost lives' narrative, although well-meaning, is stigmatising and harmful, and fuels damaging approaches based on prohibition, punishment and criminalisation.
Rêgo et al. argue that, despite the positive progress enabled by the Portuguese model, its limited ambitions, lack of update, and regressions toward punitive responses have severely undermined its potential.
EMCDDA explores the epidemiology of drug-related health problems in prisons, discussing available harm reduction measures and persistent challenges in these settings.
Kvamme et al. suggest that a significant proportion of Danish users of cannabis as medicine are motivated by a desire to alleviate their ailments whilst minimising the negative side effects that they associate with legal prescription drugs.
Grisaffi et al. argue that the successes of coca regulation in Bolivia could be replicated in Peru, as long as efforts centre community empowerment and participation.
La 64e session de la CND a été marquée par l'importance accrue des récits relatifs à la santé et aux droits humains, par le "format hybride" des débats et par un changement bienvenu et attendu depuis longtemps de la position des États-Unis sur la réduction des risques.
Dame Carol Black analyses trends and impact of thriving informal drug markets in England, and provides recommendations on how to address health-related challenges.
L'IDPC et HRI documentent les perturbations et les défis, ainsi que les développements positifs auxquels la réduction des risques a été confrontée en relation avec la pandémie de COVID-19.
Le manuel explique comment les fournisseurs de services peuvent améliorer leurs initiatives de santé avec les HSH, en particulier dans les pays asiatiques.
